Quick Answer
BioXcel Therapeutics, Inc. reported Earnings Per Share Diluted of $5.73 (loss) per share for the year ending 2025.
- BioXcel Therapeutics, Inc. showed an increase of +75.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), BioXcel Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 51.2%.
- Historical annual values: Fiscal year 2025: $5.73 (loss) per share | Fiscal year 2024: $23.51 (loss) per share | Fiscal year 2023: $98.33 (loss) per share | Fiscal year 2022: $5.92 (loss) per share | Fiscal year 2021: $4.05 (loss) per share | Fiscal year 2020: $3.79 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: